Could Catabasis Pharmaceuticals Incorporated (NASDAQ:CATB) Go Up After Its Newest Short Interest Report?

January 14, 2018 - By Henry Gaston

 Could Catabasis Pharmaceuticals Incorporated (NASDAQ:CATB) Go Up After Its Newest Short Interest Report?

The stock of Catabasis Pharmaceuticals Incorporated (NASDAQ:CATB) registered an increase of 10.58% in short interest. CATB’s total short interest was 240,400 shares in January as published by FINRA. Its up 10.58% from 217,400 shares, reported previously. With 231,200 shares average volume, it will take short sellers 1 days to cover their CATB’s short positions. The short interest to Catabasis Pharmaceuticals Incorporated’s float is 2.3%.

The stock decreased 1.28% or $0.02 during the last trading session, reaching $1.54. About 274,447 shares traded or 1.63% up from the average. Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) has declined 73.74% since January 14, 2017 and is downtrending. It has underperformed by 90.44% the S&P500.

Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products based on safely metabolized and rationally targeted linker drug discovery platform in the United States. The company has market cap of $35.55 million. The firm offers Edasalonexent, an investigational oral small molecule, which is in Phase I/II clinical trial for the treatment of duchenne muscular dystrophy (DMD). It currently has negative earnings. It is also involved in developing SMART linker conjugates that are in preclinical stage of development, including CAT-5571 for cystic fibrosis (CF) trafficking and function of CF transmembrane conductance regulator, as well as for the clearance of Pseudomonas aeruginosa; and CAT-4001 for the treatment of severe and rare neurodegenerative diseases, such as Friedreich's ataxia and amyotrophic lateral sclerosis.

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) Ratings Coverage

Among 5 analysts covering Catabasis Pharmaceuticals (NASDAQ:CATB), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Catabasis Pharmaceuticals had 14 analyst reports since August 17, 2015 according to SRatingsIntel. Wedbush maintained it with “Outperform” rating and $17 target in Wednesday, June 8 report. The company was maintained on Thursday, August 10 by Cowen & Co. Wedbush maintained the stock with “Buy” rating in Monday, August 17 report. The stock of Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) earned “Buy” rating by Citigroup on Thursday, June 9. The firm has “Buy” rating given on Monday, August 14 by Oppenheimer. As per Monday, August 14, the company rating was maintained by H.C. Wainwright. The firm has “Buy” rating by Citigroup given on Tuesday, March 22. The rating was upgraded by Citigroup to “Buy” on Monday, November 20. The stock has “Hold” rating by Cowen & Co on Thursday, October 5. The firm has “Buy” rating given on Monday, August 14 by Wedbush.

More notable recent Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) news were published by: Seekingalpha.com which released: “Catabasis Pharmaceuticals’ (CATB) CEO Jill Milne on Q3 2017 Results – Earnings …” on November 10, 2017, also Businesswire.com with their article: “Phase 2 Trial of Edasalonexent in Duchenne Muscular Dystrophy in a Late …” published on September 14, 2017, Seekingalpha.com published: “Catabasis Pharmaceuticals Could Be A Strong Investment Opportunity In 2017” on April 12, 2017. More interesting news about Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) were released by: Businesswire.com and their article: “Trial Evaluating Edasalonexent in Duchenne Muscular Dystrophy and Plans to …” published on October 04, 2017 as well as Businesswire.com‘s news article titled: “Catabasis Pharmaceuticals to Present Results from Joint Research Collaboration …” with publication date: September 28, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.



Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: